LIK066
Total Payments
$6.3M
Transactions
219
Doctors
9
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $4,060 | 2 | 0 |
| 2019 | $129,214 | 32 | 1 |
| 2018 | $1.8M | 95 | 5 |
| 2017 | $4.4M | 90 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.3M | 211 | 100.0% |
| Consulting Fee | $1,500 | 1 | 0.0% |
| Travel and Lodging | $530.71 | 3 | 0.0% |
| Food and Beverage | $248.47 | 4 | 0.0% |
Payments by Type
Research
$6.3M
211 transactions
General
$2,279
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND DOSE FINDING STUDY TO EVALUATE THE CHANGE IN WEIGHT AFTER 24 WEEKS OF TREATMENT WITH 8 DOSES OF LIK066 COMPARED TO PLACEBO IN OBESE OR OVERWEIGHT ADULTS FOLLOWED BY 24 WEEKS TREATMENT WITH 2 DOSES OF LIK066 AND PLACEBO | Novartis Pharmaceuticals Corporation | $2.3M | 0 |
| A RANDOMIZED OPEN LABEL TWO PART THREE PERIOD CROSS OVER STUDY TO INVESTIGATE THE EFFECTS OF CARBOHYDRATE IN DIET AND TO EVALUATE SUPPLEMENTS ON THE GASTROINTESTINAL TOLERABILITY OF LIK066 IN OVERWEIGHT OR OBESE SUBJECTS | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| AN OPEN LABEL PARALLEL GROUP STUDY TO ASSESS THE EFFECT OF LIK066 ON URINARY GLUCOSE EXCRETION PHARMACOKINETICS SAFETY AND TOLERABILITY FOLLOWING MULTIPLE DOSE ADMINISTRATION IN PATIENTS WITH DECREASED RENAL FUNCTION COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION | Novartis Pharmaceuticals Corporation | $904,597 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP DOSE FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELILTUS PATIENTS WITH HEART FAILURE | Novartis Pharmaceuticals Corporation | $425,896 | 0 |
| A RANDOMIZED DOUBLE BLIND DOSE FINDING STUDY TO EVALUATE THE CHANGE IN WEIGHT AFTER 24 WEEKS OF TREATMENT WITH 8 DOSES OF LIK066 COMPARED TO PLACEBO IN OBESE OR OVERWEIGHT ADULTS FOLLOWED BY 24 WEEKS TREATMENT WITH 2 DOSES OF LIK066 AND PLACEBO | NOVARTIS PHARMACEUTICALS CORPORATION | $373,517 | 0 |
| AN OPEN LABEL SINGLE CENTER SINGLE DOSE STUDY IN HEALTHY ADULT MALE VOLUNTEERS TO ASSESS THE ABSORPTION METABOLISM AND EXCRETION OF A SINGLE ORAL DOSE OF 100 MG 14C LIK066 | Novartis Pharmaceuticals Corporation | $258,346 | 0 |
| A 12 WEEK RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF LIK066 IN OBESE PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $213,690 | 1 |
| A RANDOMIZED, SUBJECT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED PHARMACODYNAMIC STUDY OF ORAL LIK066 IN OVERWEIGHT AND OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME | Novartis Pharmaceuticals Corporation | $27,749 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP DOSE FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELILTUS PATIENTS WITH HEART FAILURE | NOVARTIS PHARMACEUTICALS CORPORATION | $15,301 | 4 |
| A RANDOMIZED DOUBLE BLIND DOSE FINDING STUDY TO EVALUATE THE CHANGE IN WEIGHT AFTER 12 WEEKS TREATMENT WITH 4 DOSES OF LIK066 COMPARED TO PLACEBO IN JAPANESE PATIENTS WITH OBESITY DISEASE | NOVARTIS PHARMACEUTICALS CORPORATION | $5,213 | 2 |
| A 12 WEEK RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF LIK066 IN OBESE PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | Novartis Pharmaceuticals Corporation | $3,636 | 1 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLET GROUP DOSE FINDING STUDY TO EVALUATE THE CHANGE IN HBA1C AFTER 12 WEEKS MONOTHERAPY WITH SEVEN DOES OF LIK066 COMPARED WITH PLACEBO OR SITAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES | Novartis Pharmaceuticals Corporation | $2,600 | 0 |
| A RANDOMIZED, SUBJECT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED PHARMACODYNAMIC STUDY OF ORAL LIK066 IN OVERWEIGHT AND OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME | NOVARTIS PHARMACEUTICALS CORPORATION | $600.00 | 1 |
Top Doctors Receiving Payments for LIK066
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Madison, WI | $6.3M | 199 |
| , MD | Cardiovascular Disease | Rochester, NY | $9,688 | 2 |
| , MD | Diagnostic Radiology | Rochester, NY | $4,695 | 4 |
| , MD | Cardiovascular Disease | Rochester, NY | $4,438 | 1 |
| , MD | Specialist | Cape Coral, FL | $2,031 | 4 |
| , MD | Gastroenterology | Dallas, TX | $1,500 | 1 |
| , DO | Pediatrics | Springfield, MO | $600.00 | 1 |
| , MD | Gastroenterology | New York, NY | $556.86 | 4 |
| Stephen Harrison | — | Live Oak, TX | $198.03 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $24.29 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.3M
- Total Doctors 9
- Transactions 219
About LIK066
LIK066 is a drug associated with $6.3M in payments to 9 healthcare providers, recorded across 219 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $4,060 was paid across 2 transactions to 0 doctors.
The most common payment nature for LIK066 is "Unspecified" ($6.3M, 100.0% of total).
LIK066 is associated with 13 research studies, including "A RANDOMIZED DOUBLE BLIND DOSE FINDING STUDY TO EVALUATE THE CHANGE IN WEIGHT AFTER 24 WEEKS OF TREATMENT WITH 8 DOSES OF LIK066 COMPARED TO PLACEBO IN OBESE OR OVERWEIGHT ADULTS FOLLOWED BY 24 WEEKS TREATMENT WITH 2 DOSES OF LIK066 AND PLACEBO" ($2.3M).